Treatment satisfaction in Type 2 diabetes patients starting once daily insulin detemir

被引：0
|
作者：
Smith, I. C. [1 ]
Hansen, J. B. [2 ]
机构：
[1] Novo Nordisk Ltd, Pricing & Hlth Econ Unit, Gatwick, W Sussex, England
[2] Novo Nordisk AS, Bagsvaerd, Denmark
来源：
DIABETIC MEDICINE | 2008年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P245
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Weekly Insulin May Be as Effective as Once Daily for Type 2 Diabetes
    Anderer, Samantha
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2024, 332 (17):
  • [32] An analysis of the cost-effectiveness of starting insulin detemir in insulin-naive people with type 2 diabetes
    Home, Philip
    Baik, Sei Hyun
    Gonzalez Galvez, Guillermo
    Malek, Rachid
    Nikolajsen, Annie
    JOURNAL OF MEDICAL ECONOMICS, 2015, 18 (03) : 230 - 240
  • [33] Once-daily insulin glargine requires a significantly lower dose than insulin detemir twice daily to achieve good glycaemic control in patients with type 2 diabetes failing oral therapy
    Swinnen, S. G. H.
    Dain, M. P.
    Aronson, R.
    Roberts, D.
    Davies, M.
    Gerstein, H. C.
    Pfeiffer, A. F. H.
    DeVries, J. H.
    Hoekstra, J. B. L.
    Holleman, F.
    DIABETOLOGIA, 2009, 52 : S380 - S380
  • [34] COMPARISON OF COSTS OF THE INSULIN TREATMENT OF TYPE 2 DIABETES MELLITUS WITH INSULIN GLARGINE AND INSULIN DETEMIR
    Guisasola, Alvarez F.
    Puente, Mauricio D.
    Coscolin, Garcia T.
    Terres, Rubio C.
    VALUE IN HEALTH, 2010, 13 (07) : A287 - A287
  • [35] The safety and efficacy of adding once-daily insulin detemir to oral hypoglycaemic agents in patients with type 2 diabetes in a clinical practice setting in 10 countries
    Khunti, K.
    Caputo, S.
    Damci, T.
    Dzida, G. J.
    Ji, Q.
    Kaiser, M.
    Karnieli, E.
    Liebl, A.
    Ligthelm, R. J.
    Nazeri, A.
    Orozco-Beltran, D.
    Pan, C.
    Ross, S. A.
    Svendsen, A. L.
    Vora, J.
    Yale, J. -F.
    Meneghini, L. F.
    DIABETES OBESITY & METABOLISM, 2012, 14 (12): : 1129 - 1136
  • [36] Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight Type 2 diabetes patients -: The PREDICTIVE™ BMI clinical trial
    Montanana, C. Fajardo
    Herrero, C. Hernandez
    Fernandez, M. Rivas
    DIABETIC MEDICINE, 2008, 25 (08) : 916 - 923
  • [37] Switching patients with type 1 and type 2 diabetes on basal-bolus regimen from twice-daily NPH to once-daily insulin detemir leads to improved control and safety
    Aczel, Stefan
    Hansen, Jes B.
    Tsur, Anat
    DIABETES, 2007, 56 : A544 - A544
  • [38] Improved glycaemic control with once-daily insulin glargine in people with type 2 diabetes inadequately controlled on insulin detemir/OAD combination therapy (RESOLUTE)
    Lieverse, L.
    Rodriguez, M.
    Czupryniak, L.
    Landgraf, W.
    Pilorget, V.
    Dain, M. -P.
    Kvapil, M.
    DIABETOLOGIA, 2012, 55 : S389 - S389
  • [39] Insulin analogues dosing and costs - comparing real-life daily doses of insulin detemir and insulin glargine in type 2 diabetes patients
    Marie Jakobsen
    Mette Dalsgaard
    Morten Hørmann
    Daniél Vega Møller
    BMC Endocrine Disorders, 12
  • [40] Effect of Once-Daily Detemir vs NPH Insulin on Body Weight and Metabolic Control When Added to OADs in Type 2 Diabetes
    Catrinoiu, Doina
    Veresiu, Ioan Andrei
    Botnariu, Eosefina Gina
    DIABETES, 2009, 58 : A521 - A521
12345